Table 2 Changes in migraine characteristics, the use of analgesics and serum CGRP levels before and after supplementation with vitamin D or placebo in episodic migraine patients
|  | Vitamin D Group (n = 38) | Placebo Group (n = 36) | P value for baseline comparison | P value for end of trial comparison | ||
|---|---|---|---|---|---|---|
Baseline | After 12 Weeks | Baseline | After 12 Weeks | |||
Serum 25OHD Levels (ng/ml) | ||||||
 Mean (SD) | 27.31 (12.30) | 39.65 (13.45) | 33.70 (11.08) | 33.95 (12.14) | 0.017 | 0.062£ |
 Changes from baseline | 12.34 (6.34) | −0.28 (5.90) |  |  | ||
P value for within-group comparison | < 0.001# | 0.782# |  |  | ||
Number of Headache Days per month | ||||||
 Mean (SD) | 8.04 (3.35) | 5.07 (2. 82) | 7.69 (3.39) | 7.26 (3. 86) | 0.644 | 0.006£ |
 Adjusted mean (95%CI) |  | 4.71 (3.64–5.77) |  | 6.43 (5.28–7.58) |  | 0.031 δ |
 Changes from baseline | −2.90 (3.03) | - 0.14 (2.91) |  | |||
P value for within-group comparison | < 0.001# | 0.776# |  |  | ||
Migraine Related Disability (MIDAS score) | ||||||
|  | 29.75 (18. 54) | 19.38 (16. 43) | 36.87 (21. 55) | 35.36 (19. 45) | 0.117 | < 0.001£ |
 Adjusted mean (95%CI) |  | 21.49 (16.22–26.77) |  | 31.16 (25.51–36.82) |  | 0.016 δ |
 Changes from baseline | −10.38 (12.29) | 0.33 (14. 82) |  | |||
P value for within-group comparison | < 0.001# | 0.893# |  |  | ||
Serum CGRP levels (ng/L) | ||||||
 Mean (SD) | 195.27 (78.45) | 167.961 (80.112) | 166.05 (58.32) | 176.71 (72.22) | 0.063 | 0.626£ |
 Adjusted mean (95%CI) |  | 153.26 (133.03–173.49) |  | 188.35 (167.15–209.54) |  | 0.022 € |
 Changes from baseline | −27.31 (59.69) | 12.57 (23.85) |  | |||
P value for within-group comparison | 0.006# | 0.004# | Â | Â | ||